Wayne Strouse
Family Medicine · Penn Yan, NYNPI 1790744043
Payments from drug & device makers
Across 445 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$896
- AstraZeneca$876
- Amgen$870
- GSK$687
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$390
- plus $2K from 19 others
What the payments were for
- Food & beverage$7,52099%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 101 | $1,518 |
| Lilly USA, LLC | 51 | $896 |
| AstraZeneca | 39 | $876 |
| Amgen | 47 | $870 |
| GSK | 37 | $687 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 27 | $390 |
| AbbVie(2 entities) | 20 | $336 |
| Boehringer Ingelheim | 19 | $334 |
| Johnson & Johnson | 23 | $319 |
| Amarin Pharma, Inc. | 18 | $304 |
| Merck | 17 | $241 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $144 |
| Exact Sciences | 7 | $125 |
| Teva Pharmaceuticals USA, Inc. | 6 | $101 |
| Pfizer | 5 | $96 |
| Biohaven Pharmaceuticals, Inc. | 4 | $76 |
| Paratek Pharmaceuticals, Inc. | 3 | $51 |
| Sanofi-aventis U.S. LLC | 1 | $46 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $31 |
| Genentech USA, Inc. | 2 | $29 |
| Phathom Pharmaceuticals, Inc. | 1 | $21 |
| Corcept Therapeutics | 1 | $19 |
| Gilead | 1 | $13 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$7,567 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 25 | $31,221 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 66 | $20,343 |
| OxycontinOxycodone Hcl | 13 | $18,216 |
| XareltoRivaroxaban | 17 | $17,999 |
| Repatha SureclickEvolocumab | 11 | $17,468 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $16,545 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $11,591 |
| GlyxambiEmpagliflozin/Linagliptin | 12 | $11,562 |
| JardianceEmpagliflozin | 14 | $11,169 |
| EliquisApixaban | 15 | $8,573 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 28 | $5,877 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 12 | $5,223 |
| Tramadol Hcl ErTramadol Hcl | 12 | $4,483 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $4,366 |
| Fentanyl | 24 | $2,698 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Glyxambi, Jardiance | $334 | $39,27639 claims |
| Novo NordiskOzempic | $1,518 | $31,22125 claims |
| PfizerAbrysvo, Eliquis | $96 | $28,91681 claims |
| GSKTrelegy Ellipta, Shingrix, Anoro Ellipta | $687 | $22,69151 claims |
| Johnson & JohnsonXarelto | $319 | $17,99917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Penn Yan
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.